ALS Therapy Access Reauthorization

What This Bill Does

This bill would extend a federal program aimed at speeding access to promising therapies for people living with ALS. It is designed to help patients get faster access to treatments that may slow the disease or improve quality of life.

For ordinary Americans, the bill matters because ALS is a devastating, fast-progressing disease with few treatment options, and faster access to therapies can make a meaningful difference for patients and families. It also supports the broader medical system by encouraging continued development and review of treatments for rare, serious conditions.

Who This Bill Affects

For the general public, the bill would mainly affect people with ALS, their caregivers, and clinicians involved in ALS treatment. Most Americans would not see a direct day-to-day change, but the bill could improve access to experimental or newly approved therapies for a small but highly affected patient population.

Latest Status

May 21, 2026

Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.